摘要
目的:检测ANXA1和EGFR在胃癌中的表达,并探讨其变化与胃癌预后的关系。方法:在含有1072例胃癌的组织芯片上,利用免疫组化检测ANXA1和EGFR在胃癌中的表达,分析其与胃癌的关系。结果:免疫组化显示,ANXA1在胃癌中的表达率为35.5%(381/1072),而癌旁上皮中均有表达。在胃癌中,ANXA1的表达下降与肿瘤浸润深度、淋巴结转移、疾病分期以及组织学分化高度相关(P<0.01)。EGFR在胃癌中的表达率为22.6%(242/1072),EGFR的过度表达与肿瘤部位、高分化和T分期相关(P<0.05)。生存分析表明ANXA1和EGFR是判断胃癌患者预后的独立指标。结论:ANXA1缺失表达和EGFR的过度表达在胃癌的发生发展过程中可能起着重要作用,ANXA1和EGFR是与胃癌患者的预后密切相关的指标。
Objective：To investigate ANXA1 and EGFR expression and determine its clinical significance in gastric carcinoma. Methods：Tissue microarray blocks containing tumor specimens obtained from 1 072 patients were constructed. Expressions of ANXA1 and EGFR in these specimens were analyzed using immunohistochemical（IHC） studies. Results：IHC showed that expression of ANXA1 was observed in 381 cases（35.5% ） of 1 072 primary tumors. Loss ANXA1 expression was significantly associated with advanced T stages, lymph node metastases, advanced disease stage, and poor histological differentiation（P 〈 O. O1 ）. The rate of EGFR positive expression was 22. 6% （242/1 072）. The overexpression of EGFR had a significant relationship with tumor location, differenti- ation and T stage（ P 〈 O. 05 ）. Loss of ANXA1 expression and overexpression of EGFR had a significant correlation with poor survival both in univariate and multivariate analyses. Conclusion：The results showed ANXA1 and EGFR expression significantly changed with the progression of gastric cancer, suggesting the importance of ANXA1 and EGFR as biomarkers in cancer development and progression. ANXA1 and EGFR expression may be used to predict the progrosis of patients.
出处
《临床肿瘤学杂志》
CAS
2008年第8期691-694,共4页
Chinese Clinical Oncology
基金
"十一五"国家科技支撑计划重大项目(2006BA102A05)
